# 407: The mysterious case of Eli Lilly's obesity drug

Page: https://stenobird.com/podcast/the-readout-loud-1134305/407-the-mysterious-case-of-eli-lilly-s-obesity-drug
Text version: https://stenobird.com/podcast/the-readout-loud-1134305/407-the-mysterious-case-of-eli-lilly-s-obesity-drug.md
Podcast: [The Readout Loud](https://stenobird.com/podcast/the-readout-loud-1134305)
Published: 2026-06-25T18:55:00+00:00
Episode link: https://traffic.megaphone.fm/TTSAA8014095271.mp3
Audio file: https://traffic.megaphone.fm/TTSAA8014095271.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/407-the-mysterious-case-of-eli-lilly-s-obesity-drug
Duration seconds: 2565

## Resource

Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company's obesity candidate, retatrutide, through the FDA’s “compassionate use” program. We also discuss the resurgence of M&A, Lilly's interest in a hair loss drug, and then the FDA's reversal on rare disease drugs.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/407-the-mysterious-case-of-eli-lilly-s-obesity-drug/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-readout-loud-1134305/407-the-mysterious-case-of-eli-lilly-s-obesity-drug.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.